Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies
Sara Zehtabcheh; Hamed Soleimani Samarkhazan; Marjan Asadi; Mitra Zabihi; Sahar Parkhideh; Mohammad Mohammadi · 2025 · Biomarker Research
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Acute myeloid leukemia (AML) with KMT2A rearrangements (KMT2A-r) represents a highly aggressive and prognostically unfavorable subtype of leukemia, often resistant to standard treatments and associated with high relapse rates. KMT2A-r, found in 3-10% of adult AML cases, disrupt epigenetic regulation by forming chimeric proteins that activate oncogenic pathways like HOXA and MEIS1. These fusion proteins recruit cofactors such as Menin and DOT1L, driving leukemogenesis through abnormal histone methylation. Diagnosing KMT2A-r AML requires precision, with traditional methods like FISH and RT-PCR b
Abstract by Sara Zehtabcheh; Hamed Soleimani Samarkhazan; Marjan Asadi; Mitra Zabihi; Sahar Parkhideh; Mohammad Mohammadi, Biomarker Research (2025) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Power and Predictive Accuracy of Polygenic Risk Scores
Negative / Null Result ReportLocoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases
Negative / Null Result ReportCritical aspects of using bacterial cell viability assays with the fluorophores SYTO9 and propidium iodide
Negative / Null Result ReportAlpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Negative / Null Result ReportA randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy
Negative / Null Result ReportThe CAFA challenge reports improved protein function prediction and new functional annotations for hundreds of genes through experimental screens
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.1186/s40364-025-00786-y